Jasper Therapeutics (JSPR) to Release Earnings on Monday

Jasper Therapeutics (NASDAQ:JSPR) is expected to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Jasper Therapeutics to post earnings of ($0.46) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 9:30 AM ET.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.47. On average, analysts expect Jasper Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Jasper Therapeutics Stock Performance

JSPR traded up $0.05 during mid-day trading on Monday, reaching $0.98. 125,167 shares of the stock were exchanged, compared to its average volume of 586,136. The stock has a market capitalization of $27.38 million, a PE ratio of -0.21 and a beta of 3.08. The company has a 50 day moving average price of $1.09 and a two-hundred day moving average price of $1.52. Jasper Therapeutics has a 1 year low of $0.62 and a 1 year high of $7.19.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on JSPR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Tuesday, April 21st. UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Monday, March 23rd. They set a “neutral” rating on the stock. Finally, Rodman & Renshaw initiated coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.88.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new stake in Jasper Therapeutics during the first quarter valued at about $46,000. Engineers Gate Manager LP purchased a new stake in Jasper Therapeutics during the second quarter valued at about $78,000. Panagora Asset Management Inc. purchased a new stake in Jasper Therapeutics during the fourth quarter valued at about $35,000. Voleon Capital Management LP purchased a new stake in Jasper Therapeutics during the third quarter valued at about $50,000. Finally, XTX Topco Ltd purchased a new stake in Jasper Therapeutics during the second quarter valued at about $152,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.